Published in Circ Res on February 25, 2010
Effect of Migalastat on Cardiac Involvement in Fabry Disease (MAIORA) | NCT03838237
MicroRNAs in stress signaling and human disease. Cell (2012) 6.93
Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J (2010) 4.47
Extracellular microRNA: a new source of biomarkers. Mutat Res (2011) 2.55
Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation (2011) 2.52
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest (2014) 2.06
Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res (2012) 1.78
MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett (2012) 1.73
In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet (2011) 1.69
RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ Res (2010) 1.66
MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One (2011) 1.60
Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res (2011) 1.47
MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One (2013) 1.46
What do we know about the cardiac benefits of exercise? Trends Cardiovasc Med (2014) 1.45
Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis (2011) 1.43
Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med (2014) 1.34
Circulating microRNAs and aerobic fitness--the HUNT-Study. PLoS One (2013) 1.20
Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med (2012) 1.20
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19
Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo) (2013) 1.14
Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci U S A (2014) 1.14
MicroRNAs in cardiac disease. Transl Res (2011) 1.13
Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med (2013) 1.12
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One (2011) 1.12
Functions of microRNAs in cardiovascular biology and disease. Annu Rev Physiol (2012) 1.10
Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood (2013) 1.10
Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One (2013) 1.09
MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med (2013) 1.08
MicroRNAs expression profiles in cardiovascular diseases. Biomed Res Int (2014) 1.06
MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc (2014) 1.05
Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol (2015) 1.04
MicroRNAs and diabetic complications. J Cardiovasc Transl Res (2012) 1.04
Genome-wide identification of microRNA expression quantitative trait loci. Nat Commun (2015) 1.04
MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med (2011) 1.01
The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci (2014) 1.00
MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci (2013) 0.99
Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction. Dis Markers (2013) 0.99
MicroRNAs and the glomerulus. Exp Cell Res (2012) 0.97
Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases. Biomed Res Int (2015) 0.97
The complexity, function and applications of RNA in circulation. Front Genet (2013) 0.96
Effects of simulated microgravity on expression profile of microRNA in human lymphoblastoid cells. J Biol Chem (2011) 0.93
Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One (2011) 0.93
Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J (2012) 0.92
MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci (2015) 0.92
Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet (2013) 0.92
Optimization of extraction of circulating RNAs from plasma--enabling small RNA sequencing. PLoS One (2014) 0.91
MicroRNA polymorphisms and environmental smoke exposure as risk factors for oesophageal squamous cell carcinoma. PLoS One (2013) 0.91
microRNAs in circulation are altered in response to influenza A virus infection in humans. PLoS One (2013) 0.90
Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur J Heart Fail (2014) 0.90
The mix of two worlds: non-coding RNAs and hormones. Nucleic Acid Ther (2012) 0.90
MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy. Semin Nephrol (2012) 0.90
miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet (2015) 0.89
Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One (2015) 0.89
Micromanaging abdominal aortic aneurysms. Int J Mol Sci (2013) 0.89
MicroRNA profiling of pericardial fluid samples from patients with heart failure. PLoS One (2015) 0.88
MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. J Cell Mol Med (2015) 0.88
Transcriptomic biomarkers of cardiovascular disease. Prog Cardiovasc Dis (2012) 0.88
STAT3 regulation of and by microRNAs in development and disease. JAKSTAT (2012) 0.88
Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg (2013) 0.88
MicroRNAs as circulating biomarkers for heart failure: questions about MiR-423-5p. Circ Res (2010) 0.88
MicroRNAs: redefining mechanisms in cardiac disease. J Cardiovasc Pharmacol (2010) 0.87
Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J Card Fail (2012) 0.87
Modulation of miRNAs in Pulmonary Hypertension. Int J Hypertens (2015) 0.86
Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. FEBS Lett (2013) 0.86
Extracellular RNAs: development as biomarkers of human disease. J Extracell Vesicles (2015) 0.85
Dissecting the roles of microRNAs in coronary heart disease via integrative genomic analyses. Arterioscler Thromb Vasc Biol (2015) 0.85
Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction. PLoS One (2014) 0.85
Translational study of microRNAs and its application in kidney disease and hypertension research. Clin Sci (Lond) (2012) 0.85
Principal component analysis-based unsupervised feature extraction applied to in silico drug discovery for posttraumatic stress disorder-mediated heart disease. BMC Bioinformatics (2015) 0.85
Circulating microRNA expression profile and systemic right ventricular function in adults after atrial switch operation for complete transposition of the great arteries. BMC Cardiovasc Disord (2013) 0.85
Circulating MicroRNAs as Biomarkers in Health and Disease. J Clin Diagn Res (2012) 0.85
The biology of circulating microRNAs in cardiovascular disease. Eur J Clin Invest (2015) 0.85
Biomarkers of coronary artery disease: the promise of the transcriptome. Curr Cardiol Rep (2014) 0.84
Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res (2011) 0.84
The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease. Sci Rep (2015) 0.84
Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS One (2015) 0.83
miRSeq: a user-friendly standalone toolkit for sequencing quality evaluation and miRNA profiling. Biomed Res Int (2014) 0.83
Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol (2015) 0.83
Circulating miR-765 and miR-149: potential noninvasive diagnostic biomarkers for geriatric coronary artery disease patients. Biomed Res Int (2015) 0.82
Identification of a new target of miR-16, Vacuolar Protein Sorting 4a. PLoS One (2014) 0.82
Epitranscriptional regulation of cardiovascular development and disease. J Physiol (2014) 0.82
miRNA-548c: a specific signature in circulating PBMCs from dilated cardiomyopathy patients. J Mol Cell Cardiol (2013) 0.82
MicroRNA and Heart Failure. Int J Mol Sci (2016) 0.81
Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev (2014) 0.81
MicroRNAs and heart failure diagnosis: MiR-acle or MiR-age? Circ Res (2010) 0.81
Novel insights into miRNA in lung and heart inflammatory diseases. Mediators Inflamm (2014) 0.81
MicroRNA: A new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc Med (2016) 0.81
Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int J Cardiol (2014) 0.81
microRNA: Diagnostic Perspective. Front Med (Lausanne) (2015) 0.80
Na/K-ATPase signaling regulates collagen synthesis through microRNA-29b-3p in cardiac fibroblasts. Physiol Genomics (2015) 0.80
Desregulated microRNAs in aging-related heart failure. Front Genet (2014) 0.80
MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle. Cardiol Young (2013) 0.80
Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases. Biomed Res Int (2015) 0.80
The diagnostic value of circulating microRNAs for middle-aged (40-60-year-old) coronary artery disease patients. Clinics (Sao Paulo) (2015) 0.80
Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds. BMC Vet Res (2014) 0.79
TLR4 Expression Is Associated with Left Ventricular Dysfunction in Patients Undergoing Coronary Artery Bypass Surgery. PLoS One (2015) 0.79
Detection and comparison of microRNA expression in the serum of Doberman Pinschers with dilated cardiomyopathy and healthy controls. BMC Vet Res (2013) 0.79
Noncoding RNAs in vascular disease. Curr Opin Cardiol (2014) 0.79
Myocardial remodeling, an overview. Heart Fail Rev (2011) 0.79
Systems Biology and Noninvasive Imaging of Atherosclerosis. Arterioscler Thromb Vasc Biol (2016) 0.79
MicroRNAs in right ventricular (dys)function (2013 Grover Conference series). Pulm Circ (2014) 0.79
The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev (2006) 4.18
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res (2012) 4.06
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation (2005) 3.30
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation (2008) 2.96
Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation (2008) 2.95
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation (2002) 2.67
Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Coll Cardiol (2009) 2.59
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation (2005) 2.42
Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet (2005) 2.36
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med (2006) 2.16
Reversible isolated left ventricular non-compaction? Int J Cardiol (2008) 2.15
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Invest Dermatol (2005) 2.06
Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A (2005) 1.99
Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation (2003) 1.96
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A (2007) 1.92
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res (2010) 1.90
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med (2010) 1.87
Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87
Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res (2003) 1.82
Large expression differences in genes for iron and zinc homeostasis, stress response, and lignin biosynthesis distinguish roots of Arabidopsis thaliana and the related metal hyperaccumulator Thlaspi caerulescens. Plant Physiol (2006) 1.76
Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. Heart Rhythm (2009) 1.73
Irreversible electroporation: just another form of thermal therapy? Prostate (2014) 1.71
Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet (2008) 1.67
Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol (2006) 1.63
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation (2005) 1.55
Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension (2006) 1.53
High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol (2012) 1.53
Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One (2007) 1.51
Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res (2004) 1.51
Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J Clin Invest (2010) 1.50
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Forkhead box protein P1 as a downstream target of transforming growth factor-β induces collagen synthesis and correlates with a more stable plaque phenotype. Atherosclerosis (2011) 1.48
Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol (2012) 1.48
Thrombus aspiration alone during primary percutanous coronary intervention as definitive treatment in acute ST-elevation myocardial infarction. Catheter Cardiovasc Interv (2012) 1.47
T-cell-mediated inflammatory activity in the stellate ganglia of patients with ion-channel disease and severe ventricular arrhythmias. Circ Arrhythm Electrophysiol (2014) 1.45
Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation (2005) 1.43
Histopathology of aspirated thrombus and its association with ST-segment recovery in patients undergoing primary percutaneous coronary intervention with routine thrombus aspiration. Catheter Cardiovasc Interv (2011) 1.42
Clinical and angiographic predictors and prognostic value of failed thrombus aspiration in primary percutaneous coronary intervention. JACC Cardiovasc Interv (2011) 1.42
Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J (2011) 1.41
Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41
Association between complex coronary artery stenosis and unstable angina and the extent of plaque inflammation. Am J Med (2003) 1.41
The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. Crit Care Med (2015) 1.41
Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol (2003) 1.40
Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol (2010) 1.39
The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation (2003) 1.37
Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm (2010) 1.36
Myocardin is a bifunctional switch for smooth versus skeletal muscle differentiation. Proc Natl Acad Sci U S A (2007) 1.35
Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res (2008) 1.32
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med (Berl) (2004) 1.27
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol (2006) 1.25
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation. Cell Metab (2013) 1.24
Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem (2002) 1.23
Post-natal myogenic and adipogenic developmental: defects and metabolic impairment upon loss of A-type lamins. Nucleus (2011) 1.19
Expression differences for genes involved in lignin, glutathione and sulphate metabolism in response to cadmium in Arabidopsis thaliana and the related Zn/Cd-hyperaccumulator Thlaspi caerulescens. Plant Cell Environ (2007) 1.17
Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci U S A (2008) 1.17
Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost (2012) 1.16
Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation (2013) 1.14
Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation (2007) 1.13
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol (2008) 1.12
Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis (2003) 1.12
Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol (2008) 1.11
Biologically relevant effects of mRNA amplification on gene expression profiles. BMC Bioinformatics (2006) 1.11
MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration. Genes Dev (2012) 1.10
Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem (2007) 1.10
Critical assessment of human metabolic pathway databases: a stepping stone for future integration. BMC Syst Biol (2011) 1.10
Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology (2009) 1.09
Gene expression in early stage cervical cancer. Gynecol Oncol (2008) 1.08
Stem cells and their derivatives can bypass the requirement of myocardin for smooth muscle gene expression. Dev Biol (2005) 1.08
The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol (2003) 1.07
Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation (2004) 1.07
Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J Exp Med (2007) 1.06
N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension (2002) 1.06
Microvascular proliferation in congenital vascular malformations of skin and soft tissue. J Clin Pathol (2006) 1.05
Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. Eur J Heart Fail (2013) 1.05
Mechanisms of age-dependent response to winter temperature in perennial flowering of Arabis alpina. Science (2013) 1.04
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscul Disord (2003) 1.04
Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis. Am J Pathol (2007) 1.03
Heart failure: advances through genomics. Nat Rev Genet (2011) 1.01
Dominant-negative control of cAMP-dependent IKs upregulation in human long-QT syndrome type 1. Circ Res (2011) 1.00